A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

PHASE3CompletedINTERVENTIONAL
Enrollment

4,636

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 28, 2018

Study Completion Date

July 12, 2019

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV F vaccine with adjuvant

BIOLOGICAL

Formulation buffer

Trial Locations (88)

1010

Research Site NZ003, Grafton

1500

Research Site ZA006, Benoni

1781

Research Site PH001, Alabang

Research Site PH002, Muntinlupa

2001

Research Site ZA003, Hillbrow

2013

Research Site ZA001, Soweto

2025

Research Site NZ001, Papatoetoe

3010

Research Site AU008, Melbourne

3100

Research Site BD001, Sylhet

3148

Research Site AU011, Clayton

4000

Research Site AR003, San Miguel de Tucumán

4101

Research Site AU010, Brisbane

4400

Research Site AR008, Salta

5000

Research Site AR006, Córdoba

5006

Research Site AU007, Adelaide

5500

Research Site AR011, Mendoza

6008

Research Site AU009, Perth

6021

Research Site NZ004, Wellington

6850

Research Site ZA011, Worcester

7505

Research Site ZA004, Parow

7553

Research Site ZA010, Bellville

7646

Research Site ZA009, Paarl

8140

Research Site NZ002, Christchurch

9301

Research Site ZA008, Bloemfontein

13210

Research Site US086, Syracuse

13790

Research Site US087, Johnson City

15213

Research Site US021, Pittsburgh

15706

Research Site ES004, Santiago de Compostela

20010

Research Site US040, Washington D.C.

23220

Research Site US100, Richmond

27710

Research Site US020, Durham

28046

Research Site ES003, Madrid

28310

Research Site US097, Fort Bragg

35058

Research Site US035, Cullman

35233

Research Site US115, Birmingham

39531

Research Site US098, Biloxi

40202

Research Site US096, Louisville

41012

Research Site ES001, Seville

45322

Research Site US089, Englewood

48235

Research Site US101, Detroit

50266

Research Site US090, West Des Moines

60611

Research Site US095, Chicago

64460

Research Site MX001, Monterrey

67010

Research Site US038, Augusta

67502

Research Site US031, Hutchinson

68516

Research Site US102, Lincoln

68701

Research Site US025, Norfolk

70006

Research Site US039, Metairie

71301

Research Site US126, Alexandria

75605

Research Site US094, Longview

76550

Research Site US125, Lampasas

77030

Research Site US019, Houston

77036

Research Site US128, Houston

77555

Research Site US083, Fort Worth

Research Site US043, Galveston

77702

Research Site US116, Beaumont

78229

Research Site US042, San Antonio

80045

Research Site US134, Aurora

80204

Research Site US036, Denver

83221

Research Site US037, Blackfoot

83404

Research Site US119, Idaho Falls

83687

Research Site US032, Nampa

84107

Research Site US121, Salt Lake City

84124

Research Site US008, Salt Lake City

84132

Research Site US099, Salt Lake City

85004

Research Site US123, Phoenix

85712

Research Site US103, Tucson

85941

Research Site US129, Whiteriver

86504

Research Site US130, Fort Defiance

87301

Research Site US131, Gallup

90057

Research Site US127, Los Angeles

90255

Research Site US114, Huntington Park

92324

Research Site US092, Colton

93637

Research Site US091, Madera

94201

Research Site US093, Riverside

98105

Research Site US041, Seattle

4070038

Research Site CL003, Concepción

5311523

Research Site CL002, Osorno

8360160

Research Site CL001, Santiago

07753

Research Site US088, Neptune City

C1426BOR

Research Site AR002, Buenos Aires

0380

Research Site ZA007, Thabazimbi

0152

Research Site ZA002, Soshanguve

08035

Research Site ES002, Barcelona

BS2 8EG

Research Site UK004, Bristol

SW17 0RE

Research Site UK001, London

OX3 7LE

Research Site UK002, Oxford

SO16 6YD

Research Site UK003, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Novavax

INDUSTRY